Xencor (XNCR) Projected to Release Earnings on Wednesday

Xencor (NASDAQ:XNCR) is anticipated to announce its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Xencor to announce earnings of ($0.8017) per share and revenue of $18.8890 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The firm had revenue of $4.52 million during the quarter, compared to analysts’ expectations of $27.86 million. During the same quarter in the prior year, the company earned ($0.66) EPS. Xencor’s quarterly revenue was down 86.2% on a year-over-year basis. On average, analysts expect Xencor to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Xencor Stock Performance

XNCR opened at $20.21 on Monday. Xencor has a 12-month low of $6.92 and a 12-month high of $21.76. The firm has a 50 day moving average of $14.86 and a two-hundred day moving average of $13.14. The firm has a market capitalization of $1.50 billion, a PE ratio of -8.83 and a beta of 0.86.

Analyst Ratings Changes

XNCR has been the topic of a number of research reports. Wedbush reiterated an “outperform” rating and issued a $26.00 price objective on shares of Xencor in a research note on Thursday. Truist Financial reduced their target price on shares of Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Zacks Research raised shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research report on Wednesday, June 24th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Xencor presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.25.

Institutional Investors Weigh In On Xencor

Institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC raised its holdings in Xencor by 118.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 3,018 shares during the period. E Fund Management Co. Ltd. acquired a new stake in Xencor in the second quarter valued at approximately $79,000. iSAM Funds UK Ltd acquired a new stake in Xencor in the second quarter valued at approximately $122,000. Prelude Capital Management LLC purchased a new stake in shares of Xencor in the third quarter valued at approximately $139,000. Finally, Creative Planning increased its position in shares of Xencor by 25.3% in the second quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 3,661 shares in the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.